HOME >> BIOLOGY >> NEWS
Progress toward artificial photosynthesis?

This release is also available in German.

Plants can do it: they simply grab carbon dioxide out of the air and covert it into biomass. In this process, known as photosynthesis, the plants use light as their energy source. Chemists would also like to be able to use CO2 as a carbon source for their synthetic reactions, but it doesnt work just like that. A team headed by Markus Antonietti at the Max Planck Institute for Colloids and Interfaces has now taken an important step toward this goal. As described in the journal Angewandte Chemie, they have successfully activated CO 2 for use in a chemical reaction by using a special new type of metal-free catalyst: graphitic carbon nitride.

"Chemical activation of carbon dioxide, meaning its cleavage in a chemical reaction," explain chemists Goettmann, Thomas and Antonietti, " is one of the biggest challenges in synthetic chemistry." The bonds in this molecule are very stable, so a lot of energy is needed to split them. To date, only a few special metal catalysts are known to be capable of breaking the CO bonds in CO2.

In contrast to most previous approaches, Antoniettis team worked with metal-free catalysts, turning toward plants for inspiration. Photosynthesis in modern green plants involves an important intermediate step: the bonding of CO2 to nitrogen atoms to form carbamates. The German researchers thus also experimented with nitrogen-rich catalysts with structures that allow them to form carbamates. Their new class of catalysts is made of flat, graphite-like layers. The individual layers consist of ring systems involving carbon and nitrogen atoms. This porous material, called graphitic carbon nitride, is very heat-stable and, although it enters into many chemical interactions, it is so stable that it nearly always re-formsan ideal catalyst. It can even be used to activate carbon dioxide. It was thus possible to oxi
'"/>

Contact: Markus Antonietti
pape@mpikg.mpg.de
49-331-567-9500
John Wiley & Sons, Inc.
12-Mar-2007


Page: 1 2

Related biology news :

1. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
2. Progress toward a targeted therapy for a specific form of leukemia
3. Progress against sarcoma
4. 2nd annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research awarded to Webster K. Cavenee
5. Progress in battle against life-threatening acute allergy
6. Progress report on Homogeneous Assay project
7. Progress being made in exploring potential use of stem cells to treat heart disease
8. Media Invite: Dinner to award prize for Progress in Cancer Research
9. Progress needed on global regime for access to genetic resources and benefit-sharing
10. Albert Szent-Gyrgyi Prize for Progress in Cancer Research announced
11. Progress toward a new remedy for chronic urinary tract infections?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/7/2018)... ... September 05, 2018 , ... ... mAb manufacturing facility late last year, IPS-Integrated Project Services, LLC and G-CON Manufacturing ... autologous cell therapies. The iCON solution provides a pre-fabricated modular cleanroom infrastructure for ...
(Date:8/31/2018)... ... August 30, 2018 , ... CallTower is pleased to announce Jason ... of telecommunications experience and over ten years in executive leadership. Prior to joining CallTower, ... in early 2018. , In this new role, Jason will manage ...
(Date:8/29/2018)... CAMBRIDGE, Mass. (PRWEB) , ... August 28, 2018 ... ... QipWorks, today introduced an annual awards program that recognizes women of excellence in ... recipient. , Sponsored by QipWorks, the Johanna Dwyer Women in IP Award aims ...
Breaking Biology News(10 mins):
(Date:9/7/2018)... ... September 06, 2018 , ... ... and commercialization, is releasing the agenda for its upcoming user conference. , ... industries discussing the latest challenges, opportunities, and approaches to regulatory compliance and quality ...
(Date:9/1/2018)... ... August 31, 2018 , ... ... of the impact of a proprietary biofield energy treated nutraceutical supplement used in ... for immune function response and blood, as well as, organ-specific inflammation. The reported ...
(Date:8/29/2018)... , ... August 28, 2018 , ... ... enhanced spinal implants, announced today the successful completion of a $5.5 million funding ... Corporation, Purdue’s Foundry Investment Fund, Commenda Capital, and Ellipsis Ventures. , “Our investment ...
(Date:8/29/2018)... ... August 28, 2018 , ... CEO and founder ... safety study performed on an allogeneic (donor derived) stem cell product for osteoarthritis ... conference in September. He is also the organizer of Breakout Session 4: ...
Breaking Biology Technology:
Cached News: